FindTrial
Sign In

TO SEE EFFECT OF JEEVANIYA GHANA VATI IN HIV POSITIVE PATIENTS

CLINICAL EVALUATION OF JEEVANIYA GHANA VATI IN HIV POSITIVE PATIENTS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022412
Enrollment
70
Registered
2019-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: JEEVANIYA GHANA VATI: JEEVANIYA GHANA VATI 500 MG 2BD BEFORE MEALS WITH COW MILK 150 ML AND COW GHEE 5 ML FOR 90 DAYS Control Intervention1: Antiretroviral treatment: Ongoing Antiretro

Sponsors

DR ANUJA HARI GHOLAP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: HIV positive cases will be taken ELISA, Western blot test,CD4 cell count Inclusion criteria- 1) Patients willing to participate and giving informed consent 2) Patient of either sex or transgender diagnosed cases of HIV 3) Age group between >18 to 60 years. 4) Patients of CD4 cell count equal to or above 200 cells / micro litre 5) Patient not having multiple complications or opportunistic secondary infections Exclusion criteria- 1) Patients not willing to participate and giving informed consent 2) Patients suffering from AIDS defining illness (According to WHO criteria) 3) CD4 cell count less than 200 cells/microlitre 4) Patients having multiple opportunistic infections and with complications along with any serious illness 5) Pregnancy 6) Lactation 7) Any other criteria other than inclusion criteria

Exclusion criteria

Exclusion criteria: Exclusion criteria- 1) Patients not willing to participate and giving informed consent 2) Patients suffering from AIDS defining illness (According to WHO criteria) 3) CD4 cell count less than 200 cells/microlitre 4) Patients having multiple opportunistic infections and with complications along with any serious illness 5) Pregnancy 6) Lactation 7) Any other criteria other than inclusion criteria

Design outcomes

Primary

MeasureTime frame
Assessment of the effect of Jeevaniya ghana vati on CD4 cell count at 12 weeks after starting the trial drug randomly assignedTimepoint: 90 DAYS—

Secondary

MeasureTime frame
1) Assessment of any new or recurrent disease progression, events. 2) Assessment of the add on effect of Jeevaniya ghana vati on parameters like Agnimandya, Jwara (Fever), Body weight, Dravamalapravrutti (Diarrhoea), Haemogram. 3) Study of the immuno-modulatory mode of action of Jeevaniya ghana vati in HIV positive patients. Timepoint: 90 DAYS—

Countries

India

Contacts

Public ContactANUJA HARI GHOLAP

BHARATI VIDYAPEETH COLLEGE AND HOSPITAL OF AYURVEDA

drsunandapedhekar@gmail.com9423241800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026